Yaoming biology and NBE company of Switzerland establish a comprehensive cooperation in ADC drug development and production

April 9, 2019 / AP / -- the world's leading open platform company of biopharmaceutical technology, Yaoming biology, and NBE therapeutics, a Swiss innovative biopharmaceutical enterprise focusing on the development of new generation of innovative tumor immune activating antibody coupled drugs (immune-stimulatoryac or IADC), announced today that both sides will establish the development and production of nbe-002, the first ADC product of NBE therapeutics Face to face cooperation Nbe-002 is an immunoactive antibody coupling drug with the best potential of its kind and targeting at cancer target ror1 It is expected to enter clinical trials in 2020 to treat Sanyin breast cancer and other solid tumors Based on the company's exclusive patent technology platform, NBE therapeutics develops a new generation of targeted IADC anticancer drugs, aiming to improve the treatment scheme of cancer patients who have not yet met the treatment needs SMAC technology with self-developed ADC site-specific coupling Gamma NBE therapeutics can develop long-term antitumor immunoactivated ADC products with good drug homogeneity and stability Yaoming biology has built an integrated R & D and production center for antibody coupled drugs, providing global partners with one-stop R & D and production services from antibody to antibody coupled drug stock solution and preparations This time, the two sides will strongly support NBE therapeutics products to carry out clinical trials of new drugs in the world Dr ULF gravender, chief executive officer of NBE therapeutics, said, "Pharma is one of the world's leading cdmos for biopharmaceutical development and production, and we are very excited to cooperate with it NBE is committed to the development of innovative therapies with long-term anti-tumor immune effect We believe that Yaoming biology will provide strong support for the development of these promising cancer therapies, and accelerate the company's IADC project from pre clinical development to clinical trial stage We look forward to working with pharmacobiology in the next few years to provide more treatment options for cancer patients around the world " "We are very pleased that NBE therapeutics has chosen Yaoming biology as a long-term partner to promote the development of its unique industry-leading ADC technology platform, the first ror1 targeted ADC project with great therapeutic potential." Dr Chen Zhisheng, CEO of YaoMing bio, said, "this cooperation once again demonstrates the high-quality integrated service ability of YaoMing bio, which will further promote the rapid growth of the company's European market share In Switzerland alone, we are very excited that Yaoming biology has authorized 7 partners to develop more than 10 projects We are committed to enabling our partners at home and abroad to discover, develop and produce various types of innovative biopharmaceuticals for the benefit of our patients through our strong biopharmaceutical technology capability in line with international quality standards and the world's leading capacity scale " About NBE therapeutics NBE therapeutics, founded in 2012, is an innovative biopharmaceutical company focusing on the development of new generation ADC products, which will be clinically proven to improve the treatment of cancer patients The company's leading patent technology platform covers all aspects of ADC product development, including transpo mabdisplay for antibody discovery Gamma Platform, SMAC technology that couples antibody and active molecule at specific location Gamma Platform and new strong active molecular platform The company has been backed by bringer Ingelheim venture capital, PPFCapitalPartnersFund, NovoHoldings and other private investors As a Hong Kong listed company, Yaoming bio (Stock Code: 2269 HK) is the world's leading open, integrated bio pharmaceutical capability and technology enabling platform The company provides a full range of end-to-end R & D services for global biopharmaceutical companies and biotechnology companies, helps anyone and any company to discover, develop and produce biopharmaceuticals, realizes the whole process from concept to commercial production, accelerates the global R & D process of biopharmaceuticals, reduces the cost of research and development, and benefits patients As of December 31, 2018, 205 comprehensive projects have been developed on the platform, including 97 in the preclinical research stage, 94 in the early clinical (phase I, phase II), 13 in the late clinical (phase III) and 1 in the commercial production stage It is estimated that by 2021, the total capacity of the company's planned biopharmaceutical production bases in China, Ireland, Singapore and the United States will be about 220000 liters, which will effectively ensure that the company will provide customers with biopharmaceuticals that meet global quality standards through a sound and strong global supply chain network.